Dade Behring
This article was originally published in The Gray Sheet
Executive Summary
Equity stake in the clinical diagnostics firm by diversified drug maker Hoechst AG will increase to approximately 50% following the completion of a $400 mil. share repurchase program by Dade Behring. However, non-Hoechst AG shareholders, including Bain Capital, Goldman Sachs and company management, will continue to hold voting control. Hoechst AG currently holds a 32.5% share of Dade Behring